Skip to content
LeapHealth_Standard_1000px
April 12 2025

Why Home Infusion Is Safe, Effective—and Preferred by Patients

Blog Details

More patients and employers are choosing home infusion as a safe, effective alternative to hospital-based treatment for a wide range of acute and chronic disease states. Research indicates that home infusion is just as safe as hospital-based care, with no greater risk of adverse drug events, comparable or superior clinical outcomes, and reduced hospitalization rates. 

The U.S. home infusion therapy market was valued at $19.1 billion in 2023 with a projected compound annual growth rate of 7.7% through 2030. This growth is driven by multiple factors, including an aging population, increasing prevalence of chronic conditions such as cancer, diabetes and gastrointestinal disorders, and the rising demand for cost-effective, high-quality care. Specialty infusions, including monoclonal antibodies, enzyme replacement therapies and immunoglobulins, now account for over 50% of home infusion therapies. 

Established Safety and Clinical Efficacy

Biologics have been administered safely in the home since the 1980s, starting with immune globulin treatments for primary immune disease. Multiple studies confirm the safety of infliximab (Remicade and biosimilars) home infusions, with serious adverse events being rare. Similar findings apply to multiple sclerosis treatments like ocrelizumab (Ocrevus) and natalizumab (Tysabri). 

Studies have demonstrated that infusion reaction rates and adverse events for ocrelizumab were similar across home and clinic settings, with patients reporting greater confidence in home-based care. Another study found no difference in safety or effectiveness between clinic and home infusions of natalizumab.Clinical safety and effectiveness associated with home infusion isn’t limited to immunoglobulins or monoclonal antibodies - research suggested patients are no more likely to experience an adverse reaction with therapies that treat other conditions like certain cancers, enzyme therapies and others. 

At Leap Health, our clinical model prioritizes safety, personalized clinical care, and patient convenience. Safety is always at the forefront of our care, ensuring that every therapy and patient undergoes thorough medical review before being approved for home infusion. Not all therapies are appropriate for home administration, and our team carefully evaluates each case to determine suitability.

Our nurses are extensively trained to manage the complexities of specific therapies, and we collaborate closely with prescribers to establish protocols for managing adverse events. In cases where home infusion is not feasible, we leverage the Leap Transparency Network to identify local infusion centers that can provide necessary services. In March alone, we successfully administered therapies such as Xolair, Entyvio, Apretude, Remodulin, Remicade and biosimilars, Krystexxa, Ocrevus, Ultomiris, and Rituxan in the home setting, with no reported adverse events.

Our approach to home infusion emphasizes one-on-one clinical care, ensuring that each patient receives personalized attention. Patients are matched with nurses based on their specific clinical needs, allowing for continuous monitoring throughout the infusion process and strong relationship building over time. Our highly skilled nurses remain with the patient until the treatment is complete, providing individualized support and immediate intervention if necessary. They are well-versed in infusion reaction management strategies and are dedicated to delivering patient-centered care that enhances treatment adherence and safety.

Leap’s goal is to provide high quality clinical care in the convenience and comfort of a patient’s home. By receiving treatment at home, patients experience greater independence, reduced travel burden and minimized exposure to hospital-acquired infections. Flexible scheduling accommodates individual patient needs, reducing disruption to their daily lives. This high level of personalized care has contributed to Leap Health maintaining a Net Promoter Score (NPS, a widely recognized customer satisfaction metric) of 80 for patient satisfaction, demonstrating our commitment to enhancing quality of life through home infusion therapy.

Home infusion therapy is a proven, patient-preferred method that offers safety, efficacy and convenience while reducing overall healthcare costs. With a robust clinician team, and a patient-centered approach, Leap Health is leading the way in providing high-quality infusion services in the home setting.